DDInter1867 DDInter927
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Triflupromazine {u} (Compound) binds {v} (Gene) DRD1
Triflupromazine {u} (Compound) upregulates {v} (Gene) SLC2A6
Triflupromazine {u} (Compound) downregulates {v} (Gene) ZDHHC6
Triflupromazine (Compound) resembles Pipotiazine (Compound)
Triflupromazine (Compound) resembles Desipramine (Compound)
Triflupromazine (Compound) binds DRD1 (Gene)
Triflupromazine (Compound) upregulates SLC2A6 (Gene)
Triflupromazine (Compound) downregulates ZDHHC6 (Gene)